BR112012010252A2 - variantes de glicosilação de anticorpo - Google Patents

variantes de glicosilação de anticorpo

Info

Publication number
BR112012010252A2
BR112012010252A2 BR112012010252A BR112012010252A BR112012010252A2 BR 112012010252 A2 BR112012010252 A2 BR 112012010252A2 BR 112012010252 A BR112012010252 A BR 112012010252A BR 112012010252 A BR112012010252 A BR 112012010252A BR 112012010252 A2 BR112012010252 A2 BR 112012010252A2
Authority
BR
Brazil
Prior art keywords
glycosylation variants
antibody glycosylation
antibody
containing molecules
melatoproteinase
Prior art date
Application number
BR112012010252A
Other languages
English (en)
Inventor
Bernard Scallon
Jinquan Luo
Stephen Mccarthy
T Shantha Raju
Tracy Spinka-Doms
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112012010252A2 publication Critical patent/BR112012010252A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

variantes de glicosilação de anticorpo. anticorpo e outras moléculas contendo fc com variações de glicolisação na região fc mostram resistência aumentada a proteases, como pepsina, plasmina, tripsina, quimotripsina, uma matriz melatopro-teinase, uma serina endopeptidase, e uma cisteína protease. as moléculas contendo fc são úteis no tratamento de várias doenças e distúrbios.
BR112012010252A 2009-10-29 2010-10-25 variantes de glicosilação de anticorpo BR112012010252A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25598609P 2009-10-29 2009-10-29
PCT/US2010/053948 WO2011059684A1 (en) 2009-10-29 2010-10-25 Antibody glycosylation variants

Publications (1)

Publication Number Publication Date
BR112012010252A2 true BR112012010252A2 (pt) 2016-12-06

Family

ID=43991938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010252A BR112012010252A2 (pt) 2009-10-29 2010-10-25 variantes de glicosilação de anticorpo

Country Status (13)

Country Link
US (1) US20120276092A1 (pt)
EP (1) EP2494061B1 (pt)
JP (1) JP2013509415A (pt)
KR (1) KR101965585B1 (pt)
CN (1) CN102770554B (pt)
AU (1) AU2010318542B2 (pt)
BR (1) BR112012010252A2 (pt)
CA (1) CA2778809C (pt)
EA (1) EA201290241A1 (pt)
ES (1) ES2622102T3 (pt)
IL (1) IL219289A0 (pt)
MX (1) MX2012005006A (pt)
WO (1) WO2011059684A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
SG10202001596VA (en) * 2011-12-19 2020-04-29 Univ Rockefeller Non-sialylated anti-inflammatory polypeptides
CN104220603B (zh) 2012-02-10 2017-06-06 马里兰大学，巴尔的摩 抗体及其Fc片段的化学酶法糖基化工程
US9603897B2 (en) 2012-03-12 2017-03-28 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apolipoprotein D
ES2664095T3 (es) 2012-12-07 2018-04-18 Pfizer Inc. Fragmentos de anticuerpos monoméricos diseñados mediante ingeniería genética
EP3071599A4 (en) * 2013-11-18 2017-07-12 University of Maryland, Baltimore Hyper-glycosylated antibodies with selective fc receptor binding
CN106714830B (zh) * 2014-05-30 2020-08-25 上海复宏汉霖生物技术股份有限公司 抗表皮生长因子受体(egfr)抗体
EA038554B1 (ru) 2015-03-04 2021-09-14 Зе Рокфеллер Юниверсити Противовоспалительные полипептиды
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス 極性の組換え延長部を有するインスリン
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
EP3359190A4 (en) * 2015-10-05 2020-05-06 Circle33 LLC ANTIBODIES WITH IMPROVED STABILITY ABOUT DIGESTION
EP3606560A2 (en) * 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225354A (en) * 1986-08-22 1993-07-06 Molecular Diagnostics, Inc. Monoclonal antibodies specific for human glycoalbumin
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
WO1992016640A1 (en) 1991-03-18 1992-10-01 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US6030815A (en) 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US5952203A (en) 1997-04-11 1999-09-14 The University Of British Columbia Oligosaccharide synthesis using activated glycoside derivative, glycosyl transferase and catalytic amount of nucleotide phosphate
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
AU2005231359A1 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
CA2592015A1 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
CA2614046C (en) 2005-06-30 2018-05-15 Centocor, Inc. Methods of controlling properties of therapeutic proteins, fc-containing therapeutic proteins of the g2s2 alpha-(2,3)-sialylated glycoform, and uses thereof
EP1899477A4 (en) * 2005-07-01 2010-01-20 Medimmune Inc INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS
AU2006283560B2 (en) * 2005-08-19 2011-12-08 Centocor, Inc. Proteolysis resistant antibody preparations
HUE029649T2 (en) 2007-08-10 2017-02-28 Janssen Biotech Inc Immunoglobulin cleavage fragments as disease indicators and preparations for detecting and binding such fragments
US20100260751A1 (en) * 2007-09-28 2010-10-14 Raju T Shantha Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases
CA3052615A1 (en) * 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules

Also Published As

Publication number Publication date
MX2012005006A (es) 2012-06-19
IL219289A0 (en) 2012-06-28
KR101965585B1 (ko) 2019-04-04
AU2010318542B2 (en) 2015-08-27
JP2013509415A (ja) 2013-03-14
US20120276092A1 (en) 2012-11-01
CN102770554B (zh) 2016-02-17
CA2778809C (en) 2020-08-04
KR20120101404A (ko) 2012-09-13
ES2622102T3 (es) 2017-07-05
AU2010318542A1 (en) 2012-05-17
EP2494061B1 (en) 2017-01-25
EA201290241A1 (ru) 2013-02-28
CA2778809A1 (en) 2011-05-19
WO2011059684A1 (en) 2011-05-19
CN102770554A (zh) 2012-11-07
EP2494061A4 (en) 2013-05-22
EP2494061A1 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
BR112012010252A2 (pt) variantes de glicosilação de anticorpo
CO2018007556A2 (es) Moléculas biespecíficas de células t activadas por proteasas
IL217489A (en) U-pa polypeptides with specific substrate activity or activity and preparations and uses based on these polypeptides
SE0201980D0 (sv) Novel compounds
BRPI0807904A2 (pt) Inibidores das serina proteases para o tratamento de infecções de hcv
BRPI0607430A2 (pt) dispositivo oftálmico confortável e métodos de sua produção
HN2012000012A (es) Inhibidores de bace
GT200900268A (es) Polipeptidos de factor vii modificados y usos de los mismos .
MX337028B (es) Eliminacion de serina proteasas por tratamiento con dioxido de silicona finamente dividido.
BRPI0513327A (pt) composição farmacêutica sólida ou lìquida compreendendo neurotoxina botulìnica
NZ597452A (en) Variants of plasminogen and plasmin
MX2010005947A (es) Plasmina modificada de forma recombinante.
EA200900920A1 (ru) Соединения и композиции как ингибиторы активирующей канал протеазы
ATE453670T1 (de) Acrylierte hyaluronsäure
PE20081634A1 (es) Fab ab pegilado
DE602007011235D1 (de) Eckstück für eine matratze sowie matratze und entsprechendes herstellungsverfahren
MX2016007711A (es) Serpinas modificadas para el tratamiento de trastornos de la coagulacion.
NO20075702L (no) Polymersjikt med lav fuktighet i ikke-autoklav fremgangsmate
CR11692A (es) USO DE VARIANTES DE IGF-I PEGiladas PARA EL TRATAMIENTO DE TRASTORNOS NEUROMUSCULARES
TW200700057A (en) Alpha ketoamide compounds as cysteine protease inhibitors
SE0201977D0 (sv) Novel compounds
ATE520025T1 (de) Test für morbus-parkinson-therapeutika
SE0203712D0 (sv) Novel compounds
BRPI0504199B8 (pt) composições farmacêuticas baseadas em lopap e usos das ditas composições
ME00194B (me) Peptidno jedinjenje biološke aktivnosti, njegovo dobijanje i njegova primjena

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL